An Expert Panel Discussion

IZERVAY, for patients with Geographic Atrophy secondary to Age Related Macular Degeneration

Faculty

Arshad Khanani, MD, MA, FASRS

Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates and Clinical Associate Professor at the University of Nevada, Reno School of Medicine

Carl M Regillo, MD, FACS, FASRS

Chief, Retina Service, Wills Eye Hospital Professor of Ophthalmology, Sidney Kimmel Medical College at Thomas Jefferson University

Lejia Vajzovic, MD, FASRS

Associate Professor of Ophthalmology, Adult and Pediatric Vitreoretinal Surgery and Disease, Duke University Eye Center

Videos

Geographic Atrophy is a Relentless Condition

Lejla Vajzovic, MD, FASRS

Watch Now

IZERVAY Efficacy: Early and Significant Reductions in GA Growth

Carl M Regillo, MD, FACS, FASRS, Arshad Khanani, MD, MA, FASRS

Watch Now

Consistent Safety of IZERVAY

Carl M Regillo, MD, FACS, FASRS, Lejla Vajzovic, MD, FASRS

Watch Now

Case Study: Unilateral, Non-foveal GA

Arshad Khanani, MD, MA, FASRS, Carl M Regillo, MD, FACS, Lejla Vajzovic, MD, FASRS

Watch Now

Case Study: Bilateral, Non-foveal GA

Carl M Regillo, MD, FACS, Lejla Vajzovic, MD, FASRS, Arshad Khanani, MD, MA, FASRS

Watch Now

Case Study: Bilateral GA with Foveal Involvement

Lejla Vajzovic, MD, FASRS, Carl M Regillo, MD, FACS, Arshad Khanani, MD, MA, FASRS

Watch Now

GATHER Clinical Trial Design

Arshad Khanani, MD, MA, FASRS

Watch Now

GATHER Clinical Trials: Inclusion Criteria

Arshad Khanani, MD, MA, FASRS

Watch Now

Learn More

Interested in learning more about IZERVAY?

Visit IZERVAYecp.com

Important Safety Information and Indication

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information or to report an adverse event or product complaint, please call 1-800-707-4479 or send an email to medicalinformation@ivericbio.com.

Important Safety Information and Indication

See More +

CONTRAINDICATIONS

IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.

WARNINGS AND PRECAUTIONS

Endophthalmitis and Retinal Detachments
- Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
Neovascular AMD
- In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
Increase in Intraocular Pressure
- Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.

ADVERSE REACTIONS

Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.

INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information or to report an adverse event or product complaint, please call 1-800-707-4479 or send an email to medicalinformation@ivericbio.com.